This startup is making sure every follicle of hair on your head is counted. Photo via myhaircounts.com

A Houston startup has launched its first tech tool to track hair loss using AI and machine learning.

MyHairCounts created a hair density imaging kit and app based on proprietary and patent-pending software. The kit includes a variety of items such as scalp imaging guides, a comb, and gel to help individuals photograph their hair follicles at specified angles. Users then upload these photographs into the app for analyses which are delivered within 48 hours. These analyses inform the user whether or not their hair regrowth treatment is effective.

“Checking your shower or bathroom sink is simply not an accurate way to see if you are losing hair, says Gordon Little, CEO of Awareable Technologies, the parent company of the product. “Anyone who is concerned about losing their hair needs accurate information to evaluate their hair regrowth treatment. Until now, tracking your hair density was impossible.”

Little founded the company in Houston 2017, and the team has grown to 20 people working remotely across the country. The analysis process is completed using AI and machine learning. In order to develop this automation, the web developers fed the system countless images of hair follicles so that it could measure and report on hair growth or loss. According to MyHairCounts, individuals only notice hair loss after hair density has decreased by 20 to 30 percent.

“This product really is unique,” says Kenny Robinson, CMO for MyHairCounts. “If you’re concerned about hair loss, this is the only way a consumer can know whether or not what they are doing is truly working.”

MyHairCounts Hair Density Imaging Kit is available on their website and on Amazon. Currently in the soft launch of their products, they are using this time to work closely with individuals and med spas to review and improve the product prior to their official launch. You can purchase the kit for yourself, but MyHairCounts also offers kits to hairdressers looking to better serve their clients.

Using the kit and the app, individuals or hair stylists can track their own or their clients' hair loss. Image via myhaircounts.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.